The Role of HDACs as Leukemia Therapy Targets using HDI.
作者： Elahe Khodadi , Jessika Bertacchini , Tina Vosoughi , Ahmad Ahmadzadeh , Najmaldin Saki
DOI:
关键词: Cell cycle checkpoint 、 Biology 、 Immunology 、 Histone 、 Histone deacetylase 、 Transcription factor 、 Cancer research 、 Fusion gene 、 Leukemia 、 Cell 、 Acetylation
摘要: Histone deacetylases (HDACs) are the enzymes causing deacetylation of histone and non-histone substrates. deacetylase inhibitors (HDIs) a family drugs eliminating effect HDACs in malignant cells via inhibition HDACs. Due to extensive effects upon gene expression through interference with fusion genes transcription factors, cause proliferation migration cells, inhibiting apoptosis these tumor suppressor genes. Over evaluation leukemias may be new approach for diagnosis leukemia, which can present targets leukemia therapy. HDIs inhibit HDACs, increase acetylation histones, up- or down regulation some result differentiation, cell cycle arrest induction cytotoxic effects. Progress identification capable tracking several novel achievements treatment survival patients. In this review, we examine role as therapeutic various types well malignancies.
参考文章(68)
Flavio Leoni, Gianluca Fossati, Eli C Lewis, Jae-Kwon Lee, Giulia Porro, Paolo Pagani, Daniela Modena, Maria Lusia Moras, Pietro Pozzi, Leonid L Reznikov, Britta Siegmund, Giamila Fantuzzi, Charles A Dinarello, Paolo Mascagni, The Histone Deacetylase Inhibitor ITF2357 Reduces Production of Pro-Inflammatory Cytokines In Vitro and Systemic Inflammation In Vivo Molecular Medicine. ,vol. 11, pp. 1- 15 ,(2005) , 10.2119/2006-00005.DINARELLO
Peter A. Jones, Stephen B. Baylin, The fundamental role of epigenetic events in cancer Nature Reviews Genetics. ,vol. 3, pp. 415- 428 ,(2002) , 10.1038/NRG816
Ursula Storb, Ebenezer Satyaraj, Mef2 Proteins, Required for Muscle Differentiation, Bind an Essential Site in the Ig λ Enhancer Journal of Immunology. ,vol. 161, pp. 4795- 4802 ,(1998)
Daniel Antunes Moreno, Carlos Alberto Scrideli, Maria Angélica Abdala Cortez, Rosane de Paula Queiroz, Elvis Terci Valera, Vanessa Da Silva Silveira, José Andres Yunes, Silvia Regina Brandalise, Luiz Gonzaga Tone, None, Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. British Journal of Haematology. ,vol. 150, pp. 665- 673 ,(2010) , 10.1111/J.1365-2141.2010.08301.X
WenYong Chen, Hongfeng Yuan, Zhiqiang Wang, De Novo Acquisition of BCR-ABL Mutations for CML Acquired Resistance InTech. ,(2011) , 10.5772/28990
M Yoshida, M Kijima, M Akita, T Beppu, Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. Journal of Biological Chemistry. ,vol. 265, pp. 17174- 17179 ,(1990) , 10.1016/S0021-9258(17)44885-X
Jeffrey F. Waring, Keith B. Glaser, Joshua Stender, Michael J. Staver, Steven K. Davidsen, Roger G. Ulrich, Gene Expression Profiling of Multiple Histone Deacetylase (HDAC) Inhibitors: Defining a Common Gene Set Produced by HDAC Inhibition in T24 and MDA Carcinoma Cell Lines Molecular Cancer Therapeutics. ,vol. 2, pp. 151- 163 ,(2003)
Yoshitaka Sunami, Marito Araki, Yumi Hironaka, Soji Morishita, Masaki Kobayashi, Ei Leen Liew, Yoko Edahiro, Miyuki Tsutsui, Akimichi Ohsaka, Norio Komatsu, Inhibition of the NAD-Dependent Protein Deacetylase SIRT2 Induces Granulocytic Differentiation in Human Leukemia Cells PLoS ONE. ,vol. 8, pp. e57633- ,(2013) , 10.1371/JOURNAL.PONE.0057633
Masayoshi Iizuka, M Mitchell Smith, Functional consequences of histone modifications. Current Opinion in Genetics & Development. ,vol. 13, pp. 154- 160 ,(2003) , 10.1016/S0959-437X(03)00020-0
Jessica E. Bolden, Melissa J. Peart, Ricky W. Johnstone, Anticancer activities of histone deacetylase inhibitors Nature Reviews Drug Discovery. ,vol. 5, pp. 769- 784 ,(2006) , 10.1038/NRD2133